| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2144537 | Lung Cancer | 2006 | 9 Pages |
Abstract
The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC. DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS “QoL today”, which was not significant.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Chandra P. Belani, Jose R. Pereira, Joachim von Pawel, Anna Pluzanska, Vera Gorbounova, Eckhard Kaukel, Karin V. Mattson, Rodryg Ramlau, Aleksandra Szczesna, Panos Fidias, Michael Millward, Frank Fossella,